||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Omega Diagnostics Share Discussion Threads
Showing 1476 to 1500 of 1500 messages
|Yes - definitely coming in range...We are due news on CE mark accreditation of the Pune facility but it is either news of the Allersys divestment (positively) and/or news of the successful CD4 device validation that will trigger a rerate.I think mid-March is the likely timeline. Don't know why - just feel it, but I am also expecting a leaky sieve and for some price manipulation (to the downside) ahead of news to allow some mugging of nervous PIs.|
|Looking like you might get your wish longshanks re 16.5p
Been having a really in depth look at all the director share options and the first tranche issued to Evans, Shepherd and Harbinson with exercise price at 19p expire on 10 December 2018 having been issued on 10 December 2008.
I am sure they would have been expecting ODX's share price to be much higher by now over 9 years later as it has gone nowhere really since then.
The next sizeable batch issued to Shepherd, Harbinson and Grewal with exercise price at 14.5p expire on 5 July 2022 but share price must be 25p or higher.
Interestingly David Evans doesn't have any other options other than the one which expires next December, but having said that he was very generously 'allowed' to purchase 2,760,134 shares at 12p on 17 Dec 2010 in a private placing in relation to the purchase of the ALLERGOPHARMA IVD BUSINESS.
His average share price purchase by the way is 12.81p, Jag Grewal's is 19.92p, not so easy to work out Harbinson's and Shepherd's as they they were directors in ODX before reverse takeover in 2006 but my best guess for Harbinson is 12.88p and 9.38p for Shepherd.
My average share price in ODX has gone up significantly from my first purchase in April 2012 at 10.25p but at just over 16p I am still confident that exciting times are ahead, just not sure how long I might have to wait like the rest of us!|
|longshanks - I do understand. I was feeling a little flippant at the time but I too pay attention to averages and I too have lots of these!
Patience is the game and all the pieces are slowly but surely fitting into place. I am confident we will be well placed come the time when you just won't be able to pick these up at anything other than a premium|
|Unfortunately it means a huge deal to those involved.It is all to do with moving averages and my overall average price.I really do have an awful lot of these and it hasn't been a great performer; so that too makes it difficult to justify further purchases. Now if the price dropped to 16.5p, that would make a difference.|
|What difference does .5p make if you believe as I do that this will be worth a great deal more at some point? Bite the bullet!|
|GODDAMIT!My greedy toad is most unhappy|
|Loving your inner thoughts and dilemma longshanks, as many as you want @ 17.95p per share 😁|
|Getting easier: can now buy below 18p again.I have a little voice in my head that says "but you have too many already" and a greedy little toad in my belly saying "words like sufficient are for chimps". My dilemma continues.An appointment at IDH has just been announced: CEO being replaced with new guy starting in March.|
|Contemplating a similar large buy myself - but can't get that price: best offer 18.27p.Dilemmas, dilemmas...|
|Another sizeable delayed BUY at 18.1p today in addition to the one on Friday (18.11p)
Share price in limbo at the moment awaiting news one way or another on the IDH situation it would appear.|
|I was in CRX on the basis of the free cash flow, target markets and management change. PIM too on the basis of the sector needs (Agri yield improvements and bringing back brackish water into agriculture) but sold too soon.
CRX - great little British company that began to shine (slowly building) when the management changed.
Keep an eye on HAYT. It's time will come. I don't have a position but watching.|
|Small cap value growth, with patience, can make you millions if you learn to identify the types with catalysts. That look like his MO and I can very much respect that.
HAYT is a bit of a dog currently but could turn on global nuclear build-out and low £.|
|Interesting 30 mins or so researching Mr Sneller, his current holdings as far as I am aware are:
Bango (BGO) 3,000,000 shares = 4.68%
Bioquell (BQE) minimal holding
Hayward Tyler(HAYT) 3,625,000 shares = 6.55%
Omega (ODX) 11,453,488 shares = 10.53%
Plant Impact (PIM) 2,493,000 shares = under 3%
Prior to 26 October 2016 he held 2,320,000 shares in Cyprotex a Bioscience operation who received a recommended offer of 160p from Evotec, a GERMAN 'Drug Discovery' operation.
Since he pocketed £3,712,000 from the takeover of Cyprotex he appears to have acquired a significant stake in Hayward Tyler and continued to increase his holding in Omega.
What is really interesting is that Sneller started to build his stake in Cyprotex in 2009 when the share price was around 5p and incidentally was still around those levels in early 2014.
PATIENCE IS CLEARLY HIS WATCHWORD!|
|Mr Sneller strikes me as someone looking for more than an ordinary investment return on his ever increasing position.Currently the company is not generating enough positive cash flow but once this situation changes, I can see this moving quickly to >50p.|
|Totally agree chaps. When the share is in the doldrums and it looks like nothing is happening it's worth reminding yourself of the original investment case. Is it still valid? Would you buy the share now at this price or has the story changed?
AFAIAC this is almost the perfect stock (in AIM terms) because it is solid, well run and profitable (offering less downside risk) but has potentially enormous long term upside potential but, as has been correctly pointed out, requires patience.
Fwiw I do feel it will be taken out by a larger player before it ever gets that big.|
|Hyperboreus, totally agree. The longer under the radar the better and the bigger the break out later. It will take care of itself.|
|Just to add my two penneth worth here regarding attracting a wider share base, I am not at all bothered by other investor's ignorance in Omega at the moment as I personally added to my holding when the share price dipped below 15p and have recently added upto and around the 18p mark.
A lot of the smaller investors will jump on board once it is tipped by the likes of SCSW by which time the price will likely be a good deal higher.
From my own personal experience investing in smaller companies requires a good deal of patience, self-confidence and an element of good luck.
12 months ago I was virtually the only poster on the ALT board and just look what has happened there 😛|
|barry - agree but another major share price catalyst would be a beneficial Allersys deal with IDS. And that could come anytime. IDS have a big cash pile.|
|There just seems no interest in the shares apart from a few large holders and us LTH's. Perhaps they need to do a company presentation to attract a wider share base. Because I'm not sure what will ignite the share price apart from a positive CD4 update.....|
|It would be good to know what margins can be realised from theses tests and the manufacturing capacity of the Pune factory.|
|A couple more articles FYI about the malaria test, with interesting commentary as extracted below:
"Omega said it expects CE-Marking for the malaria and pregnancy tests will achieved by the end of the current financial year, which would allow for commercialisation across 32 European countries.
Omega said the BSI accreditation for the India facility means products can now be supplied for the Indian domestic market with immediate effect, and the first commercial sale of one of its malaria tests has now been achieved."
"Group finance director Kieron Harbinson said the accreditation was the first in a three-step process, which includes CE Marking and an external evaluation from the World Health Organisation (WHO). This final step will allow Omega to bid for high volume tenders.
“The biggest opportunity will come when we can access higher volume tenders having successfully completed the WHO evaluation,” said Mr Harbinson. “The next biggest opportunity will being able to sell through our business to business channels, and the small opportunity comes from selling in India itself, which is a highly competitive marketplace.”
Mr Harbinson said the accreditation was in line with the expectations set by the business. He added that the plant was scalable in terms of additional head count and automation."|
|Update from original pharmaceutical daily article:
Sorry only just noticed it's already been posted!|
|Impressed with the pharmaceutical daily find bw well done 👍|
|They posted the same on their Facebook page. Good to see them being proactive in demonstrating their progress.
I wonder how many tests per box?|